III Convegno Congiunto delle Società Lombarda e Triveneta di Chirurgia La carcinosi peritoneale da ca colorettale. Storia naturale, scenari clinici ed.

Slides:



Advertisements
Similar presentations
Studio randomizzato di Fase II per la valutazione di un approccio di revisione chirurgica sistematica, associata a chemio-ipertermia intraperitoneale ed.
Advertisements

Diagnosis.
Colorectal NSSG Audit Day - Polyp Cancers Northumbria Healthcare NHS Trust Sarah Mills.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,
Giuliano Pre-SSO mins ASCO Z mins
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.
Colorectal carcinoma Dr.Mohammadzadeh.
Lymphadenectomy in Epithelial Ovarian Cancer
Principles of Surgical Oncology Salah R. Elfaqih.
PANCREATIC CANCER.
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.
Present and Future of Hyperthermic intraperitoneal chemo (HIPEC) in Colorectal Peritoneal Metastases Dominique ELIAS Cancer Campus, Grand-Paris.
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.
Potentially curative re-resection of recurrent CRC  Suture line recurrences  Isolated liver metastases  Isolated pulmonary metastases.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Surgery of colorectal liver metastasis
Prognosis of colon cancer compared with rectal cancer. Where lies the difference? Bjørn S. Nedrebø Stavanger University Hospital.
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.
Principles of Surgical Oncology
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Definition Signs & symptoms Treatment Root of the disease.
Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Surgery for Metastatic Brain Tumor from Breast Cancer
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Surgery As Monotherapy for Wilms’ Tumor Lisly Chéry April 15, 2010.
R3 정상완. Introduction  EGC : Tumor invasion is limited to the mucosa or submucosa, regardless of lymph node involvement.  Accumulated histopathological.
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.
Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Two-Stage Hepatectomy for Unresectable Metastases :
Bladder Cancer R. Zenhäusern.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
AOC Surgical Outcome Survey
Chang-Yun Lu, Mao-Chih Hsieh
Short-term outcome of neo-adjuvant chemotherapy
Karcinom rektuma- management
SURGICAL TREATMENT OF LIVER METASTASES FROM COLORECTAL CANCER
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Dr.Amit Gupta Associate Professor Dept. of Surgery
Amant F – Gynecological Oncology - UZ Gasthuisberg, Leuven
Prognosis of younger patients in non-small cell lung cancer
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Staging Cancer.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Dr T P E Wells 13 July 2018 Breast SSG Bath
Vulvar Cancer Women’s Hospital,School of Medicine Zhejiang University.
Volume 150, Issue 4, Pages (April 2016)
高雄長庚 大腸直腸外科 吳昆霖 盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全
Long-term Recurrence-free Survival After Standard Endoscopic Resection Versus Surgical Resection of Submucosal Invasive Colorectal Cancer: A Population-based.
Disease-specific survival
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD 
Changes in TNM 8 To be used from
Surgical resection of metachronous liver metastases
NSCLC: Staging and TNM classification
Presentation transcript:

III Convegno Congiunto delle Società Lombarda e Triveneta di Chirurgia La carcinosi peritoneale da ca colorettale. Storia naturale, scenari clinici ed impatto prognostico D.Foschi Dipartimento di Scienze Cliniche L.Sacco Università di Milano Desenzano 12 maggio 2012

Pathogenesis of peritoneal minimal residual disease WP Ceelen, 2009 D

K.L. Sodek, 2012 Disease progression and metastatic spread

AuthorN. Patients P.C. Russell (1984)945 % Minsky (1988)2944 % Jayne (2002) % Lemmens (2010)* % Mulsow (2011) % Incidence of synchronous peritoneal carcinomatosis

W.E. Lemmens, Int J Cancer, 2011 Synchronous Peritoneal Carcinomatosis and Colorectal cancer Anni % 43.6%56.4%

W.E. Lemmens, Int J Cancer, 2011 General characteristics of patients with synchronous P.C. 0.1% 0.3% 21% 3.4%

Risk of P.C. : Multivariable logistic regression W.E. Lemmens, Int J Cancer, 2011

Meta-analysis of overall and local recurrence for – vs + preresection PFCC Rekhraj S,2008

Meta-analysis of overall and local recurrence for – vs + postresection PFCC Rekhraj S,2008

PROGNOSTIC FACTORS FOR SURVIVAL IN P.C. FROM C.R.C. Median (mos)Mean (mos)P value Synchronous P.C P = 0.78 Not synchronous P.C NS Initial pTNM staging T1,T2 (n = 4) T3 (n = 76)5.37.2P = 0.5 T4 (n = 38)3.44.7NS Lymph node involvement N P = 0.13 N+76.8NS PC staging Stage I Stage II Stage III4.46.0P = Stage IV Differentiation WD and MD3.25.3P = 0.9 PD and UD5.55.3NS Ascites Yes3.75.1P = 0.6 No5.16.5NS Liver metastases Yes4.46.1P = 0.4 No5.96.1NS B.Sadeghi, 2000 Cancer

Prognostic factors in metachronous ascites DZJ Chu, Cancer, 1989 M:6 mnt

Crude survival of synchronous peritoneal carcinomatosis V.E. Lemmens,2010

Incidence of metachronous peritoneal carcinomatosis AuthoryearN.PatientsMet.P.C. Cass % Malcom % Mendenhall % Gilbert % Tong % Gunderson % Jayne % ________________________________________________ Gilbert( autopsy ser.) % Russell ( autopsy ser. ) % ________________________________________________ Mulsow (CRC-PC) % Matsuda(CRC-PC) %

Logistic regression analysis for metachronous peritoneal carcinomatosis Odds ratioP Clinical Liver metastasis2.84 (1.7 – 4.6)<0.001 Histological Tumor stage2.74( )<0.001 Nodal stage2.47( )<0.001 Venous invasion2.07( )<0.012 Perineural invasion1.57(1-2.3)<0.032 Jayne DG, 2002

Risk factors for metachronous P.C. pT4 Positive peritoneal cytology Peritoneal seeding Ovarian Involvement Perforation of the tumor Rupture of a necrotic tumor mass Intraoperative tumor spill

Risk factors for metachronous P.C. N.PatientsSynchronous P.C. Ovarian Metastase Perforated tumor Tot n:41 n:25 n: 8 n:8 % + P.C. 15(60%) 5 (62%) 3 (37%) PCI 9±6 7±5 5±2 D. Elias, 2011

Risk of local recurrence after inadvertent rectal perforation M.T. Eriksen, 2004

Synchronous colorectal PC N:153 Complete resection N:31 Non complete resection N:122 All recurrences N:24 (77%) 1 ° site of recurrence Intra-peritoneal alone N. 8 (25.8%) P.C. – extraperitoneal N:1 (3.2%) Extra-peritoneal alone N:15 (48.4%) Matsuda, 2012 Risk of metachronous carcinomatosis after CRC-PC resection

ROS MIF TNF-α IL-1, -6, -8, -10 TGF-α bFGF TGF-β Pathophysiology of ascites accumulation K.L. Sodek, 2012

SurvivaL of P.C. after standard treatment or CRS-HIPEC